Impairment of the chondrogenic phase of endochondral ossification in vivo by inhibition of cyclooxygenase-2

Janssen, M.P.F.; Caron, M.M.J.; van Rietbergen, B.; Surtel, D.A.M.; van Rhijn, L.W.; Welting, T.J.M.; Emans, P.J.

Published in:
European Cells and Materials

DOI:
10.22203/eCM.v034a13

Published: 17/10/2017

Document Version
Publisher's PDF, also known as Version of Record (includes final page, issue and volume numbers)

Please check the document version of this publication:

• A submitted manuscript is the author’s version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher’s website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page numbers.

Link to publication

Citation for published version (APA):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal?

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Download date: 27. Dec. 2018
IMPAIRMENT OF THE CHONDROGENIC PHASE OF ENDochondRAl OSSIFICATION IN VIVO BY INHIBITION OF CYCLOOXYGENASE-2

M.P.F. Janssen1,§, M.M.J. Caron1,*,§, B. van Rietbergen1,2, D.A.M. Surtel1, L.W. van Rhijn1, T.J.M. Welting1 and P.J. Emans1

1 Laboratory for Experimental Orthopaedics, Department of Orthopaedic Surgery, CAPHRI Care and Public Health Research Institute, Maastricht University Medical Centre, PO Box 5800, 6202 AZ Maastricht, the Netherlands
2 Orthopaedic Biomechanics, Department of Biomedical Engineering, Eindhoven University of Technology, PO Box 513, 5600 MB Eindhoven, the Netherlands
§ These authors contributed equally

Abstract

Many studies have reported on the effects of cyclooxygenase-2 (COX-2) inhibition on osteogenesis. However, far less is known about the effects of COX-2 inhibition on chondrogenic differentiation. Previous studies conducted by our group show that COX-2 inhibition influences in vitro chondrogenic differentiation. Importantly, this might have consequences on endochondral ossification processes occurring in vivo, such as bone fracture healing, growth plate development and ectopic generation of cartilage. The goal of our study was to investigate, in vivo, the effect of COX-2 inhibition by celecoxib on the cartilaginous phase of three different endochondral ossification scenarios.

10 mg/kg/d celecoxib or placebo were orally administered for 25 d to skeletally-immature New Zealand White rabbits (n = 6 per group). Endochondral ossification during fracture healing of a non-critical size defect in the ulna, femoral growth plate and ectopically-induced cartilaginous tissue were examined by radiography, micro-computed tomography (µ-CT), histology and gene expression analysis.

Celecoxib treatment resulted in delayed bone fracture healing, alterations in growth plate development and progression of mineralisation. In addition, chondrogenic differentiation of ectopically-induced cartilaginous tissue was severely impaired by celecoxib. In conclusion, we found that celecoxib impaired the chondrogenic phase of endochondral ossification.

Keywords: Endochondral ossification, fracture healing, growth plate development, nonsteroidal anti-inflammatory drugs, cyclooxygenase 2, celecoxib, chondrogenic differentiation.

*Address for correspondence: Marjolein M.J. Caron, PhD, Laboratory for Experimental Orthopaedics, Department of Orthopaedic Surgery, CAPHRI Care and Public Health Research Institute, Maastricht University Medical Centre, PO Box 5800, 6202 AZ Maastricht, the Netherlands. Telephone: +31 433884153 Email: marjolein.caron@maastrichtuniversity.nl

Introduction

Bone formation occurs following two mechanisms: intramembranous ossification and endochondral ossification (EO) (Marsell and Einhorn, 2011). During intramembranous ossification, mesenchymal stem cells directly differentiate into osteocytes to form new bone without formation of cartilaginous tissue (Kronenberg, 2003; Thompson et al., 2002). This process mainly takes place during cranial bone formation and healing of highly-stabilised fractures (Thompson et al., 2002). The other important mechanism is EO, which is responsible for normal long bone formation in the growth plates (Kronenberg, 2003). Growth plates are populated by highly proliferative chondrocytes, which differentiate into mineralising hypertrophic chondrocytes that either die from apoptosis or transdifferentiate into osteoblasts (Park et al., 2015; Yang et al., 2014; Zhou et al., 2014). The remaining mineralised extracellular matrix (ECM) provides a scaffold for osteoblasts and osteoclasts to adhere and remodel, setting the stage for bone apposition and, thus, longitudinal bone growth and limb development (Kronenberg, 2003; Mackie et al., 2008).

Fracture healing through EO starts with the formation of a haematoma in which mesenchymal stem cells condense and subsequently differentiate following the chondrogenic lineage towards chondrocytes. Then, the chondrocytes become...
hypertrophic and direct the formation of mineralised matrix, promote angiogenesis and finally undergo apoptosis (Marsell and Einhorn, 2011). Then, in a similar way to the growth plate, the leftover mineralised matrix is invaded by osteoblasts and osteoclasts, which will remodel the matrix into woven bone. The woven bone is gradually replaced by lamellar bone and the fracture is united. During the final phase, the newly-formed bone is remodelled to its original shape (Hadjijargyrou and O’Keefe, 2014; Kronenberg, 2003). In addition, cartilaginous tissue, ectopically generated for the purpose of cartilage repair, forms from progenitor cells by an EO process (Caldwell and Wang, 2014; Caron et al., 2014). One of the main problems in many cartilage repair strategies is the premature hypertrophic differentiation of the generated cartilage (Dickhut et al., 2009; van Osch et al., 2009).

Impaired endochondral ossification can lead to various problems. During EO, disturbances of the growth plate might lead to abnormal skeletal development. Most intensively investigated problems of EO during fracture healing are delayed union and non-union of fractures (Calori et al., 2007; Santolini et al., 2015). In contrast, too active EO can cause undesirable effects i.e. heterotopic ossification after joint arthroplasty or trauma (Spinarelli et al., 2011) and intralesional ossification in cartilage repair surgery (Bouwmeester et al., 1997; Brown et al., 2004).

To date, the exact biomolecular mechanisms involved in EO are still not fully understood. We only begin to understand the spatiotemporal roles and effects of morphogens or medications on chondrogenic differentiation during EO. However, detailed knowledge on timing and (spatiotemporal) concentration of morphogens and/or medications during chondrogenic differentiation of progenitor cells is important for correct formation of cartilage and bone tissues (Emans et al., 2012). Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used systemic inhibitors of inflammatory prostaglandin production induced by cyclooxygenases (COX-1 and COX-2) (Brooks et al., 1999). NSAIDs have inhibitory effects on fracture healing, which mainly depends on the dose and duration of the treatment (Gerner and O’Connor, 2008; Geusens et al., 2013). In addition, most studies that ascribed a role for COX-2 in bone fracture healing, focused on osteogenesis (Lau et al., 2013; O’Connor and Lysz, 2008; Simon et al., 2002; Simon and O’Connor, 2007; Zhang et al., 2011) and left chondrogenesis unstudied. Therefore, the potential effect of COX-2 inhibitors on the chondrogenic part of EO is incompletely understood. Chondrogenic differentiation precedes the ossification phase during EO and the limiting effect of COX-2 inhibitors on EO may also be ascribed to impaired chondrogenic differentiation of the mesenchymal progenitor cells.

Our previous study shows that specific COX-2 inhibitors decrease chondrocyte hypertrophic differentiation in the growth plate during the chondrogenic phase of EO (Welting et al., 2011). However, it is still unknown whether this action is specific for the growth plate or whether it affects the cartilaginous phase of endochondral ossification in a broader way. To further extend our knowledge on the influence of the COX-2 inhibitor celecoxib on the cartilaginous phase of EO, we tested it in three different in vivo compartments of the same rabbit. We studied EO during fracture healing of a non-critical size defect in the ulnae, in the growth plate and in ectopically-induced cartilaginous tissue (Emans et al., 2007; Emans et al., 2010).

Materials and Methods

Experimental design and animal model
12 female, skeletally-immature (107 ± 1.8 kg), specific-pathogen-free (SPF) New Zealand White (NZW) rabbits were used. The experiment was approved by the Maastricht University animal ethical committee (DEC 2010-027). Sample size was calculated according to the formula of L. Sachs (Sachs, 2004)

\[ n = \text{(expected standard deviation/expected effect size)}^2 \times 15.7 \]

and 6 animals per group were needed. Animals were randomly assigned to the treatment or control group. Throughout the experiment, animals were housed in groups under standard conditions with ad libitum access to water and food and 12 h of light each day. Animal well-being and behaviour (score in response to stimuli, back arch, twitch, wincing, posture, self-care, condition of skin, mobility, limb loading, difficulties in respiration/breathing, dehydration or undernourishment symptoms, colour of the mucous membranes and extremities, oedema/swelling/cold feeling and other notable abnormalities) were checked daily. 10 mg/kg celecoxib (Pfizer, New York, NY, USA) in 1 mL of Critical Carepaste (Oxbow Animal Health, St. Louis, MO, USA) was injected subcutaneously. Celecoxib green is a marker of mineralisation that, when injected, is incorporated in newly-formed bone for 24–36 h, while the unincorporated label is excreted by the kidneys within several hours (van Gaalen et al., 2010). In previous studies, we show that mineralisation during EO occurs about two weeks after initialisation of EO (Emans et al., 2005; Emans et al., 2007; Welting et al., 2011); therefore, the injection was performed at day 14 of the experiment (11 d before sacrifice). After 25 d, rabbits were euthanised by an overdose of intravenous pentobarbital. During further processing, the specimens were coded and, thus, the researchers were blinded to the treatment received.
Surgery

Non-critical sized defect
At day 0, a 5 mm non-critical size defect was created in the left ulna of all rabbits (Frame, 1980). Animals were anaesthetised by isoflurane inhalation. The skin was opened over the ulnae and the diaphysis approached. A 5 mm defect was created 25 mm above the carpal joint in the exposed ulnae using an oscillating saw, which was cooled by irrigation fluid. Due to the fibro-osseous union of ulna and radius proximal and distal to the surgical site, no fixation of the bone fragments was required (Matos et al., 2008). Muscles were replaced over the defect and the incision was closed layer by layer with Vicryl Rapide™ 4-0 absorbable sutures (Ethicon, Kirkton, Scotland). The animals were allowed full weight bearing directly after surgery.

Growth plates
The growth plate of the distal femur was examined. No surgery involving the growth plates was performed, no surgery was performed on the femur and the surgery of the tibia was equal in both groups and distal to the tibial growth plate, therefore, it was expected that surgery did not influence the growth plate of the distal femur.

Periosteal endochondral ossification
During the same surgical procedure when the non-critical size defect was created, we used the method described by Emans and colleagues, for ectopically-inducing cartilage formation, in which a subperiosteal space is created to induce periosteal endochondral ossification (PEO) (Emans et al., 2007; Emans et al., 2010). PEO was induced on both tibia, as described in literature, with minor modifications (Emans et al., 2007; Emans et al., 2010). The skin was opened over the upper medial side of the tibia, the pes anserinus was identified and the periosteum was incised just medially of the pes anserinus, leaving the semitendinosus tendon untouched. The periosteum was elevated proximally with a probe and 0.2 mL of a 2 % (w/v) agarose-based gel were injected between the bone and periosteum. The 2 % (w/v) agarose solution was prepared by dissolving 2 g of ultra-pure low-melting agarose granules (Cat no: 10975035, Lot No: MO91807; Invitrogen, Carlsbad, CA, USA) in 100 mL of 0.9 % NaCl, followed by steam-sterilisation. The preparation was warmed to 40 °C in a water bath to liquefy it prior to use. Next, gelation was accelerated by cooling the PEO location with 5 °C sterile 0.9 % NaCl. Finally, the wound was closed in separate layers with Vicryl Rapide™ 4-0 absorbable sutures (Ethicon, Kirkton, Scotland). This procedure was repeated on the contra-lateral tibia (Emans et al., 2007; Emans et al., 2010).

Prostaglandin E\(_2\) levels
To confirm COX-2 inhibition by celecoxib, we determined prostaglandin E\(_2\) (PGE\(_2\)) levels in blood plasma at day 0 and at sacrifice by standardised enzyme immunoassay (EIA) analysis (Cayman Chemicals, Ann Arbor, MI, USA). Briefly, blood was drawn at day 0 and just before sacrifice and centrifuged at 370 × g for 5 min. The blood plasma was used to perform an EIA for detection of PGE\(_2\) levels.

Radiography
Directly after sacrifice, plain radiographs of the ulnae were obtained with a mammography unit (Philips BV25; Philips, Eindhoven, the Netherlands) to determine the radiologic stage of fracture healing. Bone healing was scored according to the Lane and Sandhu radiological scoring system (Lane and Sandhu, 1987). To determine formation and mineralisation of PEO tissue, also plain radiographs of the tibia were obtained, taking care of positioning the tibia in such way that the site of PEO was visible on the radiograph.

Histology and image analysis

Non-critical size defect
The left ulnae were isolated and fixed in 4 % formalin. After the tissue was fixed, the ulnae were gradually embedded in poly(methyl methacrylate) (PMMA) (Technovit 9100; Heraeus Kulzer, Hanau, Germany). After complete polymerisation, 50 µm-saggital sections were cut using a saw microtome (SP1600; Leica, Wetzlar, Germany). Prior to the cutting of each section, a vonKossa/thionine or Masson-Goldner trichrome (Carl Roth GmbH, Karlsruhe, Germany) staining was performed to visualise different tissue structures.
types (Bulstra et al., 1993). Sections were stained for 10 min with 1% silver nitrate (AgNO₃; VWR Prolabo, Amsterdam, the Netherlands) and for 30 s with 5% sodium thiosulphate (Na₂S₂O₃; VWR Prolabo), rinsed with tap water for 5 min and finally stained for 10 min with a 0.25% thionine solution. The Masson-Goldner trichrome staining was performed according to the manufacturers’ protocol. Sections were scored using a modified version of Heiple histologic fracture scoring system (Heiple et al., 1987).

Femoral growth plates
The left distal femora were isolated and fixed in 4% formalin (VWR Prolabo). Next, the femora were gradually embedded in PMMA (Technovit 9100; Heraeus Kulzer). After complete polymerisation, 50 µm-thick sections were cut in the sagittal plane between the condyles, in the anatomical middle of the femur, using a saw microtome (SP1600; Leica). Femora were positioned perpendicular to the microtome saw to obtain reproducible sections and to prevent false measurements due to skewness. Prior to sectioning, haematoxylin/eosin (H&E; Dako, Troy, MI, USA) or no staining was applied by adding acid alcohol for 10 min, 0.6% haematoxylin for 10 min, rinsing for 10 min with tap water and adding 0.2% eosin for 5 min. Then, the H&E stained sections were further processed for microscopic analysis, using a Zeiss Axioscope A.1 microscope (Zeiss, Oberkochen, Germany), with AxioVision 4.8 software. To prevent skew measurements and improve reproducibility, growth plate sections were placed in a way that the growth plate was aligned horizontally. Then, image frames were standardised to a width of 5.0 mm (2.5 mm left and 2.5 mm right of the anatomical middle of the section). With a custom-written script in MatLab software (MathWorks, Natick, MA, USA), the average height of the proliferative and hypertrophic zone of each growth plate was determined.

The unstained sections were processed using a Leica microscope (DM RD; Leica), taking three images for each section with normal light and with filtered light, to assess the calcein green injected. Images were obtained and processed with Leica IM50 software. The three separate colour channels of the RGB images were combined with Adobe Photoshop CS3 software to create one image. Measurements on all sections were taken with AxiosVision 4.8 software and a custom-written script in MatLab (the software was calibrated before measurements). The surface area between the mineralisation front at day 14 (calcein green front) and at day 25 (status at sacrifice) was measured in a box with a standardised width of 8.0 mm. By dividing the surface area (in µm²) by the width of 8.0 mm, the total growth after incorporation was calculated for both groups.

Periosteal endochondral ossification
Tibiae were isolated, fixed in 4% formalin and decalcified for 3 weeks in 0.5 M ethylene diaminotetraacetic acid (EDTA, VWR Prolabo) pH 7.8. An additional brief (20 h) decalcification step was performed using 1:5 diluted Shandon™ TBD-1™ Decalcifier (Thermo Fisher Scientific, Waltham, MA, USA). Next, the tibiae showing PEO were dehydrated with increasing concentration of ethanol and embedded in paraffin wax. Starting from the centre, where PEO occurred, 5 µm-thick sections were cut. Tissue sections were stained with safranin O/fast green (both from Sigma-Aldrich). Slides were deparaffinised and rehydrated using standard protocols. Proteoglycans were stained with 0.1% safranin O and counterstained with 0.1% fast green. Stained sections were dehydrated and mounted with Histomount (Thermo Fisher Scientific) for subsequent microscopic analysis using a Zeiss Axioscope A.1 (with AxioVision 4.8 software).

Gene expression analysis
Cartilage tissue, ectopically-formed on the tibia or fibrous periosteal tissue (on the tibia where none or little ectopic cartilage was formed), was harvested. Tissue samples where lysed in TRIzol (Life Technologies | Thermo Fisher Scientific, Carlsbad, CA, USA) according to the manufacturer’s protocol. Sections were harvested, washed in TRIzol and stored at −70°C. RNA was isolated using TRIzol (Life Technologies | Thermo Fisher Scientific, Carlsbad, CA, USA) according to the manufacturer’s protocol. The RNA was washed in chloroform by centrifugation, ethanol precipitated and dissolved in water. RNA quality was determined using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). The 260/280 ratios were within the range of 1.9–2.1. The RNA was kept at −70°C until use.

Table 1. Primer sequences for RT-qPCR. The 5’ to 3’ forward and reverse oligonucleotide sequences used for RT-qPCR are listed.

<table>
<thead>
<tr>
<th>Oligo sets</th>
<th>Forward</th>
<th>Reverse</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acan</td>
<td>CCGGACACAAACGAGACCTAT</td>
<td>CTGGCGAGCTTCCGTAAXA</td>
</tr>
<tr>
<td>Alpl</td>
<td>GGAGGATGTGGCCGCTTCTC</td>
<td>CTGGCTAAGGCCCATCACATGAG</td>
</tr>
<tr>
<td>Col1a1</td>
<td>CTGACTGGAAGAGCGGAGATAC</td>
<td>CCAATGCGGACTGACCTTGA</td>
</tr>
<tr>
<td>Col2a1</td>
<td>TGGGTGTCTCTTTTATTTTGTCTCTCTC</td>
<td>GCTGGTGGACTACACCAGTTGAT</td>
</tr>
<tr>
<td>Col10a1</td>
<td>AACCTCGGACAAAGGCTTACA</td>
<td>CCAATCGCCCTTCCCTTGGCT</td>
</tr>
<tr>
<td>Mmp13</td>
<td>CGATGGAAGCCCAACCTTAA</td>
<td>ACTGCTAATGCGGACTCAAGGAATA</td>
</tr>
<tr>
<td>PTHrP</td>
<td>AAGGCGGATGGCCATCCAAGA</td>
<td>TCCTGGCGGTGTGGATTTC</td>
</tr>
<tr>
<td>Sox9</td>
<td>AGTACCCGCCACCTGCAAC</td>
<td>CGCTCTGCTCGCTGCTGAG</td>
</tr>
<tr>
<td>Runx2</td>
<td>TGAACGACACTCCAGCTGCTGA</td>
<td>GACCTGCGTTCGCTTTCT</td>
</tr>
<tr>
<td>Vegfa</td>
<td>GTCAAGAGGCACACATACCA</td>
<td>CATCTGCTGTCCTGAGGAA</td>
</tr>
<tr>
<td>28S rRNA</td>
<td>GCCATGGAATCCTGCATTGCTA</td>
<td>GCTCGTCGAGGCTCCATAC</td>
</tr>
<tr>
<td>p-Actin</td>
<td>GACAGGATGGCAGAAGAGATTACTG</td>
<td>CCAACGGATCCACACAGACTCTTT</td>
</tr>
<tr>
<td>GAPDH</td>
<td>ACTTTGTGGAAGCTCTACCTGGTA</td>
<td>GTGTTTGGAGGGCTTCCTACTCTT</td>
</tr>
</tbody>
</table>
CA, USA). RNA isolation, RNA quantification by ultraviolet (UV) spectrometry (Biodrop; Isogen Life Sciences, Utrecht, the Netherlands) and cDNA synthesis were performed as described before (Caron et al., 2012a; Welting et al., 2011). Real time quantitative PCR (RT-qPCR) was performed using MESAGREEN qPCR MasterMix Plus for SYBR® Assay (Eurogentec, Seraing, Belgium). A CFX96 Real-Time PCR Detection system (Biorad, Hercules, CA, USA) was used for amplification with the following protocol: initial denaturation 95 °C for 10 min, followed by 40 cycles of amplification (denaturation 15 s at 95 °C and annealing 1 min at 60 °C). Validated primer sequences used are listed in Table 1. Data were analysed using the 2−ΔΔCt method, mRNA expression was normalised to reference genes (28S rRNA, β-actin and GAPDH) and gene expression was calculated as fold change compared to control.

Statistics

Statistical analysis was performed using IBM SPSS 20.0 software (Chicago, IL, USA). Because of our group size, Mann Whitney U test was applied for all measurements. Results with \( p < 0.05 \) were regarded as significant. Data were presented as mean with standard error of the mean (SEM).

Results

Animal well-being and confirmation of COX-2 inhibition by reduced PGE\(_2\) levels

To determine the consequences of COX-2 inhibition on endochondral ossification, the skeletally-immature New Zealand white rabbits were systemically treated with celecoxib for 25 d (6 animals in control group and 6 animals in celecoxib group). Analysing blood plasma samples, we confirmed that celecoxib treatment efficiently inhibited \( \text{PGE}_2 \) synthesis by 80 % after 25 d and, thus, systemically inhibited COX-2 (Fig. 1A). Throughout the experiment, animal well-being and behaviour were observed daily. We did not observe any difference between the control and celecoxib-treated group. In addition, no significant differences were observed in the body weights during the entire experiment (Fig. 1B).

Ulnar fracture healing and COX-2 inhibition

To determine whether this systemic COX-2 inhibition influenced bone fracture healing, we employed a non-critical size defect model, which has been described before (Chai and Tang, 1986), to study fracture healing capacity.

To evaluate radiographical bone fracture healing in control and celecoxib-treated rabbits, plain radiographs were taken after 25 d of follow-up. Overall, these radiographs showed full bony bridging in all but one ulna in the control group. In the celecoxib-treated group only half of the ulnae showed full bony bridging, whereas the other half of the ulnae showed only partial bony bridging (Fig. 2A). Analysis by the Lane-Sandhu radiologic fracture scoring system, which measures bone formation, remodelling and union (Lane and Sandhu, 1987), revealed a significant difference in the average scores: 8.8 (SEM ± 0.8) in the control group vs. 5.7 (SEM ± 0.9) in the celecoxib-treated group (Fig. 2B). This indicated that fracture healing was indeed impaired in the celecoxib group.

To gain more insight in the newly-formed bone structure, bone fracture healing in the ulnae was analysed and evaluated by \( \mu \)-CT. Reconstructed 3D images confirmed the progression in fracture healing for both groups, as observed in the radiographs (Fig. 2C). \( \mu \)-CT data were analysed in greater detail by using a finite element model to predict

---

**Fig. 1.** Weight and systemic COX-2 inhibition during the experiment. (A) Systemic COX-2 inhibition was confirmed by measuring PGE\(_2\) levels in serum from pre-operative samples and in samples at day 25, just before sacrifice. PGE\(_2\) levels were measured using a PGE\(_2\)-specific EIA. Inhibition of PGE\(_2\) synthesis was determined as % decrease as compared to pre-treatment serum samples. (B) Weight of the rabbits during the experiment in the control \((n = 6)\) and celecoxib \((n = 6)\) groups. Error bars indicate SEM, asterisk \((*) = p < 0.05\), ns = not significant.
stiffness of the newly-formed bone (Fig. 2D). In both groups, one outlier was excluded from analysis due to a refracture of the sample, making the FEA unreliable. A significantly higher average compression stiffness was calculated for the control group as compared to the celecoxib-treated group [21082 N/mm (SEM ± 1172 N/mm) vs. 14707 N/mm (SEM ± 3101 N/mm), respectively; \(p = 0.048\)]. However, no significant differences were found in torsional stiffness [4416 N/mm/rad vs. 3477 N/mm/rad \( (p = 0.12)\)] and bending stiffness around the X-axis [3839 N/mm vs. 2564 N/mm \( (p = 0.09)\)] or bending stiffness around the Y-axis [2288 N/mm vs. 1949 N/mm \( (p = 0.13)\)] (Fig. 2D). These data supported the observation of impaired fracture healing in the celecoxib-treated rabbits.

After 25 d of follow-up, von Kossa/thionine and Masson-Goldner trichrome stained histological samples showed, similar to radiographs and μ-CT analyses, a delayed fracture healing in the celecoxib-treated rabbits (Fig. 3A-C). The control group showed bony bridging in all sections and reorganisation in most of the sections, only little callus tissue was still present and the cortices reorganised (Fig. 3A). In the celecoxib-treated group, full bony bridging was only observed in half of the sections. In the other half, more

<table>
<thead>
<tr>
<th>FEA analysis</th>
<th>Control (n = 6)</th>
<th>Celecoxib (n = 6)</th>
<th>(p)-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Compression stiffness (N/mm)</td>
<td>21082 ± 1172</td>
<td>14707 ± 3101</td>
<td>0.048*</td>
</tr>
<tr>
<td>Torsional stiffness (N/mm/rad)</td>
<td>4416 ± 937</td>
<td>3477 ± 577</td>
<td>0.12</td>
</tr>
<tr>
<td>Bending stiffness X-axis (N/mm)</td>
<td>3839 ± 580</td>
<td>2564 ± 479</td>
<td>0.09</td>
</tr>
<tr>
<td>Bending stiffness Y-axis (N/mm)</td>
<td>2288 ± 396</td>
<td>1949 ± 364</td>
<td>0.13</td>
</tr>
</tbody>
</table>

**Fig. 2.** Impaired fracture healing in celecoxib-treated rabbits. Impaired fracture healing after celecoxib treatment in an experimental non-critical size defect model. A 5 mm defect was created in the distal ulna. After a follow-up of 25 d, fracture healing was examined radiologically. (A) Full union in radiography of the ulna of the control group and only partial/delayed union in radiography of the ulna of the celecoxib-treated group. (B) In radiographs, bone union was assessed using the Lane-Sandhu scoring system. Significantly more union was measured in the control group, compared to the celecoxib treated group. (C) 3D reconstruction of μ-CT images of the control group ulna and the celecoxib-treated ulna. Note the cortical bridging in the control group and a gap still present in the celecoxib-treated group. (D) Bone stiffness was assessed by finite element analysis. Either a significant difference or trend towards significance were observed among various parameters in control versus celecoxib-treated group. SEM is indicated between brackets. The * indicate significant \(p\)-values.
callus tissue was still retained in the fracture region and less remodelling towards woven bone occurred (Fig. 3A). Furthermore, new bone formation and areas with retained cartilaginous tissue were still present in the fracture area of the celecoxib group whereas advanced reorganisation towards woven bone was visible in the control group (Fig. 3B). In Mason-Goldner trichrome stained sections, the celecoxib group showed more connective tissue in the fracture callus, whereas this was largely absent in the control group (Fig. 3C).

When fracture healing was quantified using an existing histological scoring system (Bos et al., 1983; Heiple et al., 1987), a significantly decreased score in the celecoxib-treated group was observed. The scoring system takes into account union, formation and remodelling of cartilaginous spongiosa, formation and remodelling of spongious bone, formation, remodelling and continuity of cortical bone (each side scored separately) and bone marrow formation. Each item can be scored from 0 to 4, a total score of 24 means a fully-healed fracture and 0 means no healing occurred at all. A mean score of only 12.00 (SEM ± 1.9) out of 24 was achieved in the celecoxib-treated group, whereas the control group achieved a mean score of 17.67 (SEM ± 1.3) out of 24. An overview of these results is shown in Fig. 3D. Overall, these data showed that systemic celecoxib treatment for 25 d in a non-critical size bone defect in skeletally-immature rabbits resulted in delayed endochondral bone fracture healing, as determined on plain radiographs, µ-CT images and histology.

**Growth plate development and COX-2 inhibition**

Systemic COX-2 inhibition delayed the bone fracture healing process in our non-critical size defect model, possibly by interfering with the endochondral ossification process. To determine whether COX-2 inhibition caused similar consequences in another scenario of endochondral ossification, we analysed growth plate development in the same rabbits. This had the additional benefit of analysing the effect of COX-2 inhibition on the EO process alone, without clouding of simultaneously occurring intramembranous ossification at the same site, as can be the case during fracture healing. In addition, the progenitor cell source for EO in the growth plate is different from in fracture healing: resting zone chondrocytes versus periosteal- and bone marrow-derived mesenchymal cells, respectively.

---

**Fig. 3.** Impaired histological fracture healing in celecoxib-treated rabbits. Delayed fracture healing as seen in histologic sections of the same specimens. (A) An overview of vonKossa/thionine and Masson-Goldner trichrome stained sections showed bony bridging of the cortex in the control group, but in the celecoxib-treated group a clear gap was still visible in the region where the defect was created. (B) A magnification of the vonKossa/thionine stained section shown in A (scale bars represent 100 µm) showed advanced reorganisation towards woven bone (#) in the control group, whereas more cartilaginous tissue (white arrow) was still present and only little reorganisation had occurred in the celecoxib-treated rabbits. (C) Masson-Goldner trichrome staining. (D) Fracture healing was significantly impaired in the celecoxib-treated rabbits, when histologically analysed by a modified version of Heiple’s histologic scoring system. SEM is depicted between brackets. The * indicate significant p-values.

---

<table>
<thead>
<tr>
<th>Heiple score</th>
<th>Control (n = 6)</th>
<th>Celecoxib (n = 6)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Union</td>
<td>3.33 (± 0.21)</td>
<td>2.33 (± 0.42)</td>
<td>0.132</td>
</tr>
<tr>
<td>Cartilaginous spongiosa</td>
<td>3.00 (± 0.26)</td>
<td>2.17 (± 0.40)</td>
<td>0.180</td>
</tr>
<tr>
<td>Spongious bone</td>
<td>2.33 (± 0.21)</td>
<td>1.50 (± 0.22)</td>
<td>0.065</td>
</tr>
<tr>
<td>Cortex bridging_1</td>
<td>3.00 (± 0.00)</td>
<td>2.33 (± 0.33)</td>
<td>0.180</td>
</tr>
<tr>
<td>Cortex bridging_2</td>
<td>3.00 (± 0.45)</td>
<td>2.00 (± 0.45)</td>
<td>0.180</td>
</tr>
<tr>
<td>Bone marrow</td>
<td>3.00 (± 0.37)</td>
<td>1.67 (± 0.33)</td>
<td>0.041*</td>
</tr>
<tr>
<td>Total</td>
<td>17.67 (± 1.28)</td>
<td>12.00 (± 1.53)</td>
<td>0.041*</td>
</tr>
</tbody>
</table>
Fig. 4. Celecoxib inhibited advancement of the mineralisation front. The distal femoral growth plate was examined histologically. (A) The calcein green mineralisation front (*) at day 14 was visualised and compared to the transition between proliferative zone and hypertrophic zone of the growth plate (#) at day 25. The surface of the growth plates was measured over a standard width of 8 mm and the average growth was calculated. The scale bars represent 1000 µm. (B) Significantly more advancement of the mineralisation front was observed in the control group compared to celecoxib-treated group. (C) In adjacent sections stained with H&E, average thickness was calculated for the total growth plate, the proliferative zone (PZ) and the hypertrophic zone (HZ). In addition, normal columnar chondrocytes could be seen in the control group growth plate and a less organised structure of the chondrocytes and a less marked transition between resting zone area (RZ) and proliferative zone was seen in the celecoxib treated rabbits. (D) A significant decrease in thickness of the total growth plate and in the hypertrophic zone was observed, but no significant difference was present in the proliferative zone. Standard error of the mean is depicted between brackets. The * indicate significant p-values (p < 0.05), ** = p < 0.01, ns = not significant.
To follow new bone formation originating from endochondral ossification in the growth plate, fluorescent calcium labelling was applied by calcein green injection at day 14 (11 d prior to sacrifice) and analysed in histological sections of the growth plate. Calcium labelling by fluorochromes, as calcein green, allows to determine the location of active mineralisation at a given time point (time of injection) (van Gaalen et al., 2010). The injection of calcein green at day 14 caused a clearly visible green fluorescent front at the diaphyseal side of the growth plate of the rabbits’ distal femora (mineralisation front) (Fig. 4A). In the same sections, the transition between proliferative zone and hypertrophic zone of the growth plate could also be observed. The distance between the fluorescent mineralisation front and the proliferative/hypertrophic transition zone was indicative of the growth that occurred between

Fig. 5. Impaired PEO formation in celecoxib-treated rabbits. A periosteal endochondral model was used to examine the influence of celecoxib on chondrogenesis. An agarose gel was injected between periosteum and bone of the upper tibia to induce PEO. (A) Plain radiographs showed (the mineralised part of) PEO (#) in control and celecoxib-treated rabbits (white arrows point to the location of injection). (B) In 67% of the injected control rabbits and in none of the celecoxib-treated rabbits PEO formation was observed. (C) Safranin O/fast green-stained histological section of the same specimen illustrating cartilage formation and mineralisation (#) in control group and in the celecoxib-treated rabbits, with no clear PEO formed (black arrows point to the location of injection). This showed that not only mineralisation was inhibited, but the lack of cartilaginous PEO formation indicated an inhibited chondrogenic differentiation. (D) Higher magnification of panel C: the transition of cartilage into the ossified part is visible in more detail. (E) Gene expression analysis of indicated genes was performed by RT-qPCR on PEO tissue in control and celecoxib-treated rabbits. Data are presented as relative expression compared to control condition and normalised to a housekeeping index consisting of 28S rRNA, β-actin and GAPDH. Bars represent mean ± SEM. * = p < 0.05, ns = not significant.
incorporation of calcein green and sacrifice. The growth for the control group was 2436 µm (± 142 µm) and for the celecoxib-treated group 1830 µm (± 54 µm), which was a significantly shorter distance (Fig. 4B). This showed that celecoxib treatment also inhibited endochondral ossification during the growth plate development.

In sequential sections stained with H&E (Fig. 4C), we further focused on the growth plates of these long bones, to determine whether the inhibition of advancement of the epiphysial mineralisation front originated from the growth plate (and, thus, the chondrogenic phase of endochondral ossification). The total thickness of the growth plates in the control rabbits was 375.1 µm (± 14.2 µm), whereas the total thickness of the growth plates in the celecoxib-treated rabbits was only 307.9 µm (± 10.34 µm) (p < 0.05). Also, and in concert with our previous work (Welting et al., 2011), the thickness of the hypertrophic zone was significantly decreased in the celecoxib-treated group (Fig. 4D). Collectively, these results showed that growth plate development was inhibited and, since growth plate development was driven by chondrogenic differentiation, it was likely that at least a part of the reduced growth plate development caused by celecoxib, could be explained by an impaired chondrogenic differentiation.

PEO and COX-2 inhibition

PEO can be used as a model for studying in vivo endochondral bone formation because, similarly to the growth plate, it sequentially completes the stages of chondrogenic differentiation during endochondral ossification (Emans et al., 2007). Different from the growth plate, PEO formation allowed for the specific analysis of the effect of COX-2 inhibition on the newly-formed endochondral ossification processes (as celecoxib treatment started almost simultaneously with induction of PEO) and, thus, study early phases of chondrogenic differentiation during EO. To study whether celecoxib not only had an influence on osteogenic differentiation, but also on chondrogenic differentiation, we implemented this method for ectopically inducing endochondral ossification in the same rabbits used for the non-critical size defect procedure. We analysed whether celecoxib treatment was able to alter PEO formation, as a model for chondrogenic differentiation, through radiography, histology and gene expression analysis. Radiography and histology showed a distinctive 67 % PEO formation (4 out of 6 injection sites) in the control group and a 0 % distinctive PEO formation (0 out of 6 injections sites) in the celecoxib-treated group (Fig. 5A, B). Safranin O staining, to detect proteoglycans, indicative of cartilage formation (Fig. 5C, D), showed that rabbits in the celecoxib-treated group did not detectably develop cartilage tissue in the PEO tissue. In Fig. 5C the tibial cortex and fibrous periosteal tissue could be seen in the celecoxib group, but no PEO tissue was developed. In the control group, cartilaginous tissue was formed, which, at the time of harvest, was gradually ossifying. This could be seen in more detail in Fig. 5D. Gene expression analysis of the PEO tissue or fibrous periosteal tissue at the site of agarose injection showed that celecoxib significantly impaired the expression of collagen type II (Col2a1), aggrecan (Acan), collagen type X (Col10a1), alkaline phosphatase (Alpl), Runt-related transcription factor 2 (Runx2) and matrix metalloproteinase 13 (Mmp13). Expression of parathyroid hormone-related peptide (PTHrP) was upregulated. No significant differences were found in the expression of SRY box 9 (Sox9), vascular endothelial growth factor alpha (Vegfa) or collagen type I (Col1a1) (Fig. 5E). Overall, these data indicated that systemic inhibition of COX-2 by celecoxib impaired the formation of PEO tissues, suggesting that, in this model, systemic COX-2 inhibition had a negative effect on the initiation of the chondrogenic phase of endochondral ossification.

Discussion

We showed that the inhibition of COX-2 by celecoxib influenced the chondrogenic phase of endochondral ossification in vivo, affecting not only fracture healing, but also growth plate development and ectopic periosteal cartilage formation.

Fracture healing by EO in a non-critical size defect in the ulna was found to be delayed on radiographs, µ-CT images and histology in the celecoxib-treated animals, which is consistent with previous reports, where COX-2 is selectively inhibited (Gerstenfeld et al., 2003c; Goodman et al., 2002; Herbenick et al., 2008; Simon et al., 2002; Simon and O’Connor, 2007). Remarkably, the non-fused fractures in the celecoxib-treated animals were characterised by the presence of retained cartilaginous tissue, which was likely indicative of delayed EO. Impaired bone healing was confirmed by FEA, in which a significant difference in compression strength was observed. Compression strength was the only parameter that differed significantly between control and celecoxib-treated groups. Compression strength largely depends on cortical integrity (Fyhrie and Vashishth, 2000) and, since the celecoxib-treated animals specifically presented lower FEA compression strength, it was likely that the mode of impaired fracture healing due to celecoxib treatment involved impaired cortical healing as a result of delayed endochondral ossification. Indeed, this was confirmed by our histological examinations.

Using a calcium-binding fluorochrome, we were able to demonstrate that the mineralisation front in the growth plate advanced less over time in the celecoxib-treated animals compared to control. This implicated an impaired advancement of endochondral-driven bone growth and confirmed our previous findings (Welting et al., 2011). In the celecoxib-treated rabbits, the growth plates were significantly shorter, which can be mainly attributed to a shorter hypertrophic zone. This shorter hypertrophic zone can be caused
by an impaired progression into hypertrophy (Welting et al., 2011). Our data strongly indicated that – apart from the possibility that osteogenic remodelling in already developed bones might be affected by celecoxib treatment – the chondrogenic phase of endochondral ossification was sensitive to the celecoxib treatment.

In addition to EO in fracture healing and growth plate development, the same animals were used to examine the chondrogenic phase of endochondral ossification, according to a previously described model for in vivo ectopic cartilage formation (Emans et al., 2007). We found that no distinctive ectopic cartilage tissue was formed in the celecoxib-treated group. Ectopic periosteal cartilage formation and the formation of cartilaginous fracture callus are de novo initiated cellular processes, requiring an initial inflammatory environment (Caron et al., 2012b; Gerstenfeld et al., 2003a; Gerstenfeld et al., 2003b). With the systemic celecoxib-dependent reduction of COX-2 activity, an essential inflammatory reaction may be dampened, resulting in an impaired initiation of chondrogenic differentiation or inflammation-driven osteogenic remodelling of fracture callus. A challenge is to define at which stage of EO COX-2 is involved and to clarify why EO seemed to be delayed in fracture healing and growth plate development, while being inhibited in the PEO model. EO can be divided into 4 stages: 1) initiation of chondrogenic differentiation of chondroprogenitor cells, 2) chondrocyte proliferation, 3) hypertrophic differentiation, 4) vascularisation and apoptosis (Caron et al., 2012b; Caron et al., 2014). Previous work from our group shows a bi-phasic COX-2 expression pattern during chondrogenic differentiation in vitro (Caron et al., 2016; Welting et al., 2011). The two stages, corresponding to COX-2 expression peaks, resemble early differentiation and chondrocyte hypertrophy. This suggests that inhibition of COX-2 could have an influence on both early chondrogenic differentiation, as well as, late chondrogenic differentiation. Therefore, inhibition of COX-2 could influence both the initiation of chondrogenic differentiation and chondrocyte hypertrophy. According to the present study, growth plate development was an already ongoing process and fracture healing and ectopic periosteal chondrogenic differentiation were initiated simultaneously to COX-2 inhibition. During fracture healing and ectopic periosteal chondrogenic differentiation, the first peak of the bi-phasic COX-2 expression was likely inhibited, whereas, in growth plate development, COX-2 inhibition might interfere with the already ongoing chondrogenic differentiation. Therefore, we speculated that it was the inhibition of this biphasic COX-2 expression that was likely to cause differential effects on fracture healing, growth plate development and ectopic periosteal chondrogenic differentiation.

The skeletal mechanism of action of arachidonic acid-derived eicosanoids remains a topic of investigation (O’Connor and Lysz, 2008). For instance, the prostanoid receptors of PGE2 (EP-1, EP-4) have different roles in chondrocyte and osteocyte differentiation and, therefore, in fracture healing. EP-1/- mice have enhanced osteoblast differentiation and accelerated fracture repair (Zhang et al., 2011), whereas EP-2 and EP-4 agonists improve fracture healing (Paralkar et al., 2003). However, in COX-2 -/- mice, fracture healing is severely impaired, but these mice have no reported skeletal abnormalities (Simon et al., 2002). The latter is inconsistent with our findings, as we observed an effect of celecoxib on the maturation of the growth plate, implicating that COX-2 played a role during endochondral ossification. Finally, in a rat model, reduction of leukotriene synthesis by inhibition of 5-lipoxygenase accelerates fracture healing by increasing COX-2 expression in fracture callus and progression into hypertrophy to complete endochondral ossification (Cottrell and O’Connor, 2009; Manigrasso and O’Connor, 2010).

COX-2 is a rate-limiting enzyme in the turnover of arachidonic acid to prostaglandins (Ledwith et al., 1997). The decreased levels of PGE2 in the rabbit blood plasma at day 25 confirmed that we were able to inhibit COX-2 activity systemically in vivo. In our experiment, we have chosen to use a celecoxib dose equivalent to 800 mg/d in humans. This is a high dose to be used in orthopaedic conditions and rheumatic diseases, but non-toxic and described as safe for use in a gastrointestinal toxicity study (Silverstein et al., 2000). It is unknown whether the effects of celecoxib, which we reported, would have also been observed if lower concentrations would have been used or with other NSAIDs. Furthermore, local instead of systemic administration of celecoxib might differently influence the course of chondrogenic differentiation, but this will be topic of further studies.

Our study design had a limitation, but at the same time an opportunity. Using a single animal for multiple experimental models could be a confounding factor, as we had no control on factors that might influence each other. This could be addressed by using separate animals for each study design. However, considering inter-animal variation when using different animals for different models, we would never have been able to make the comparison as accurate as we did using this combined model. Moreover, the potential influence of one factor on the other would be expected to be similar in each rabbit. The only difference between the two groups was the administration of celecoxib, which was the variable we aimed to test.

**Conclusions**

We confirmed previous findings according to which selective COX-2 inhibition (by celecoxib) causes impaired fracture healing (Simon et al., 2002) and, more importantly, we showed that chondrogenic differentiation during EO was impaired by COX-2
inhibition. This impaired chondrogenic differentiation had an impact on the development of the fracture callus, growth plate development and ectopic cartilage formation. The impaired fracture healing was probably at least partially a result of the effects of celecoxib on the chondrogenic phase of EO, similarly to results found for growth plate development and, therefore, not solely a consequence of impaired osteogenesis. This chondrogenic involvement may have other, yet unknown, implications for the use of COX-2 inhibitors in pregnant women, children and patients suffering from a fracture and necessitates further clinical investigation.

Acknowledgments

This work was financially supported by the Annafonds|NOREF (grant 08/42 to TW) and the Dutch Arthritis Association (LP/L14). The authors would like to thank L. Peeters (Department of Orthopaedic Surgery, MUMC, the Netherlands) for performing the gene expression analysis.

References


of TNF-alpha signaling; the role of TNF-alpha in endochondral cartilage resorption. J Bone Miner Res 18: 1584-1592.


van Osch GJ, Britberg M, Dennis JE, Bastiaansen-Jenniskens YM, Erben RG, Konttinen YT, Luyten FP

Discussion with Reviewers

Oliver Gardner: The authors have taken the unusual approach of creating multiple defects in each animal, greatly reducing the number of animals that may have otherwise been used. Based on their experience, do the authors have any comments or reflections on this approach or advice for other groups looking to perform similar experiments?

Authors: Our study design could be considered as a limitation, but at the same time it was an opportunity. Using a single animal for multiple models, all studying the same biological process (endochondral ossification), can be a confounding factor, as the researchers have no control on factors that might influence each other. This could be addressed by using different animals for each model. However, considering inter-animal variation when using different animals for different models, we would never have been able to make the comparison as accurate as we did using this combined model. Moreover, the potential influence of one factor on the other would be expected to be similar in each rabbit. The only difference between the two groups was administration of celecoxib, which was the variable we aimed to test.

When studying the influence of one variable (for instance a medication) on a biological process in vivo (such as endochondral bone fracture healing), it might be worthwhile to always keep in mind that in the same animal (a) similar biological process(es) is/are occurring or can be studied as well (such as endochondral growth plate development and ectopic cartilage formation). This is relevant for multifactorial situations, for example studying the effect of NSAIDs on bone fracture healing in a growing child. The use of NSAIDs will not only affect bone fracture healing, but potentially also growth plate development. Analysis of similar biological processes within one animal will not only result in relevant data regarding the biological process (endochondral ossification) itself but results can additionally be applied to a broader relevant clinical setting, while at the same time reducing the number of animals needed to study these processes separately.

Michael Pest: While beyond the scope of this manuscript, how much influence might behavioural changes have on this study? Changes in general activity, joint loading, gait, pain perception, etc. were not evaluated in this study and may have affected the final outcomes.

Authors: Using the ulna and both tibia in this experiment did not result in detectable weight loss (data shown in Fig. 1) and gross behavioural changes, as observed by the researchers while taking daily care of the animals. Although specific small changes may have been left un-noted, we expected that potential behavioural changes would have had no significant effect on the experimental outcomes reported in our manuscript.

Michael Pest: Considering the impressive suppression of PEO by celecoxib, should high-dose NSAIDs treatment be considered for studying the treatment of heterotopic ossification due to trauma, osteochondromas or other similar diseases?

Authors: It is unknown whether the effects of celecoxib, which we report here, would also be observed when lower concentrations would have been used or with other NSAIDs. However, NSAIDs are indeed already used to prevent heterotopic ossification (HO) after hip arthroplasty (Shehab et al., 2002). Factors that are described to influence heterotopic ossification development are prostaglandins (Balboni et al., 2006; Shehab et al., 2002). Urinary excretion of PGE, is a recommended indicator of early HO and the PGE2 blocker NSAID indomethacin is highly effective in avoiding HO formation (Brooker et al., 1973; Grohs et al., 2007; Schurch et al., 1997). Whether (a high dose of) celecoxib could be beneficial in the prevention of heterotopic ossification, caused by other events, such as trauma or a period of immobilisation, was not a topic of our study but is very well possible. We (and others) have already shown that the NSAIDs celecoxib and indomethacin negatively influence endochondral ossification in vitro (Caron et al., 2017; Welting et al., 2011). Furthermore, local, instead of systemic administration of celecoxib, may differently influence the course of chondrogenic differentiation, but this will also be topic of our future studies.

www.ecmjourn.org 215
Additional References


Editor note: The scientific editor for this paper was Mauro Alini.